Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now KOSDAQ - Delayed Quote • KRW Kolmar BNH Co Ltd (200130.KS) Follow Add holdings 16,780.00 -380.00 (-2.21%) At close: July 20 at 5:00:00 AM GMT+9 All News Press Releases SEC Filings Kolmar BNH Revolutionizes ESG with HemoHIM, an Eco-friendly Health Supplement SEOUL, South Korea, November 25, 2024--Kolmar BNH is committed to sustainable research and development, investing in eco-friendly products using green technologies HemoHim Manufacturer Kolmar BNH Receives NAI Classification from the US FDA SEOUL, South Korea, October 21, 2024--HemoHim Manufacturer, Kolmar BNH obtained a No Action Indicated (NAI) classification for its Sejong plant following an inspection by the FDA. HemoHim's Global Market Success Rooted in Rigorous Quality Control SEOUL, South Korea, August 23, 2024--HemoHim's huge success on the global stage is largely attributed to its meticulous quality control. Kolmar BNH Expedites European Market Expansion with its Technology-Driven HemoHIM G SEOUL, South Korea, July 24, 2024--Kolmar BNH widens global reach for HemoHIM G, immune-boosting and fatigue-fighting product, by expanding into SEA and Europe. Kolmar BNH Sharpens Global Competitiveness with Dual Functionality of HemoHIM SEOUL, South Korea, June 21, 2024--Kolmar BNH secured approval from the Ministry of Food and Drug Safety for the fatigue-improving function of the HemoHIM. Kolmar BNH Expands Its Global Market by Launching HemoHIM G in Taiwan SEOUL, South Korea, May 28, 2024--Kolmar BNH launches HemoHIM G, expanding its presence in the global market.